Publications by authors named "Janina Stumpf"
Long-term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long-term data collected within the GCLLSG registry. Altogether, 417 CLL patients who received first-line treatment with FCR were analyzed, of which 293 (70.
View Article and Find Full Text PDFArticle Synopsis
- The phase 2 CLL2-BAAG trial evaluated a combination therapy of acalabrutinib, venetoclax, and obinutuzumab in 45 patients with relapsed/refractory chronic lymphocytic leukemia (CLL), focusing on measurable residual disease (MRD) outcomes.
- 93.3% of patients achieved undetectable MRD (<10-4) at any time point, showing the treatment's effectiveness, including those previously exposed to other therapies.
- The study indicated high 3-year progression-free and overall survival rates (85.0% and 93.8%, respectively) and highlighted that integrating circulating tumor DNA (ctDNA) analysis with traditional methods improved early relapse detection
Purpose Of Review: In this review, we provide an overview of different time-limited combination therapies of chronic lymphocytic leukemia (CLL) and summarize the data of pivotal clinical studies. Furthermore, we discuss the relevance of MRD in clinical trials and summarize the challenges that arise in routine clinical care. Finally, we provide an outlook on studies and datasets needed to optimize the use of time-limited treatment strategies and MRD assessments in modern CLL management.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on patients with Richter transformation (RT) in chronic lymphocytic leukemia, showcasing a phase 2 trial where patients were treated with a combination of two drugs, tislelizumab and zanubrutinib, for 12 cycles.* -
- Of 48 patients analyzed, 58.3% showed a positive response to the treatment, with some achieving complete or partial remission, thus surpassing the study's response rate goal.* -
- The results indicate that this combination therapy not only has a solid response rate but also leads to a 12-month survival rate of 74.7%, though common side effects included infections and gastrointestinal issues.*